Results. Measurements of the vertical diameters (VDs) and horizontal diameters (HDs) of the FEs obtained by the Minor test were taken at 7 and 30 days after injections using Mirror imaging software, version 7.0.2 (Canfield Scientific Inc, Fairfield, New Jersey).
Field effects 1, 2, and 3 were located on the left side of the patients' backs; FEs 4, 5, and 6 on the midline; and FEs 7, 8, 9, and 10 on the right side. The mean (SD) HDs and VDs are shown in Figure 2 and listed in Table 1 and Table 2 . for Clostridium botulinum type A toxin-hemagglutinin complex used by the manufacturer, Ipsen Limited, Slough, England.) In all cases, injection sites 1, 2, and 3 are located in the first vertical column of the injection site grid (left side of the back); 4, 5, and 6 in the second vertical column (midline); and 7, 8, and 9 in the third vertical column (right side of the back). Injection site 10, not visible in the first patient at day 7, was treated in all cases with a 1-minute postinjection massage. Table 3 lists the mean HDs and VDs of the FEs resulting from first and third vertical columns of injections in the injection grids on the patients' backs, excluding those in the midlines. Table 4 lists the mean HDs and VDs of the FEs resulting from isovolumetric injections at the same concentration and depth with and without postinjection massage.
Comment. Small doses of Dysport significantly reduce the sweating around the injected points, visible by the Minor test. In the present study, smaller FEs were found in the midline, corresponding to the 0.04-mL concentration injected in 3 different depths and coincidentally the area of increased sweating. These findings suggest that the type of skin, location, and amount of previous sweating may play a more important role in the size of the Dysport FE than depth and concentration of the product. On the other hand, cases of more intense sweating might need higher doses to achieve similar FE. This could indicate a competitive mechanism of action of the toxin in the release of acetylcholine at the neuromuscular junction.
The shapes of the FEs were round or oval, and the HDs were larger than the VDs. The differences in the FE measurements also suggest that other factors might affect the FE. Table 3 lists the results from left and right columns of the injection site grid. The mean HDs and VDs of the HAs were larger at 7 and 30 days, but the larger sizes were not related to progressively deeper injections. After 30 days, the field effects at the sites of 3-and 4-mm depth injections had larger mean HDs than sites of the 2-mm injections. By volume injected, the HDs and VDs of the FEs resulting from more diluted product (0.06 mL) were larger at 7 and 30 days, the 1 exception being the mean VD of FE 9 at 30 days. However, considering the interindividual variations, the differences according to the different dilutions can be considered clinically irrelevant. Table 4 lists the results of an FE 9 and 10 comparison. Injection at the tenth injection site was followed by 1 minute of local massage and ultimately resulted in FEs with smaller HDs and VDs.
Hsu and colleagues 4 also observed that botulinum toxin type A injection diluted at higher volume resulted in greater FE and larger areas of effects on the forehead. However, a recent study 5 showed no differences with differ- Abbreviations: →, horizontal diameter; ↑, vertical diameter. a Field effects 1, 2, and 3 resulted from 0.02-mL dilution injections located in the first column of the injection site grid on the left side of the patient's back; field effects 7, 8, and 9 resulted from 0.06-mL dilution injections located in the third column of the injection site grid on the right side of the patient's back.
b Clostridium botulinum type A toxin-hemagglutinin complex (Ipsen Limited, Slough, England). 100.0, 33.3, 20.0, or 10 .0 U/mL) in the glabella. 5 New studies with higher numbers of patients are needed to confirm these preliminary results and perhaps demonstrate changes in techniques to increase the FE of botulinum toxin type A and allow treatments with fewer injections. 
